Olema Pharmaceuticals, Inc. (OLMA)

NMS – Цена в реальном времени. Валюта: USD

13.97

-0.89 (-5.99%)

При закрытии: May 12, 2026, 4:00 PM EDT

04.05.2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 154,700 shares of the Company's common stock, effective as of May 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

29.04.2026

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Prakash Raman, Ph.D., to its Board of Directors.

21.04.2026

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29-June 2 in Chicago, Illinois. The Company will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial.

02.04.2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock, effective as of April 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

22.03.2026

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

Paradigm Biocapital Advisor increased its stake in Olema Pharmaceuticals by 750,000 shares in Q4 2025. The quarter-end value of the position rose by $122.09 million, reflecting the new purchase.

18.03.2026

Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Olema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

16.03.2026

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end.

Видео

No Data

There is no data to display

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer's novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancer Continued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026 Generated $218.5 million in gross proceeds from a follow-on public offering, further strengthening the Company's balance sheet; ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities Transformation into a fully-integrated oncology company underway in preparation for the Company's first potential commercial launch in late 2027 SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens, highlighted by continued enrollment and strong investigator interest in our OPERA-01 and OPERA-02 trials,” said Sean P.

Olema Pharmaceuticals, Inc. (OLMA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Olema Pharmaceuticals, Inc. (OLMA)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Видео

No Data

Пресс-релизы

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Видео

No Data

Пресс-релизы

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Search stocks

Olema Pharmaceuticals, Inc. (OLMA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Olema Pharmaceuticals, Inc. (OLMA)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Видео

No Data

Пресс-релизы

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Видео

No Data

Пресс-релизы

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results